<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK114807" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK114807/" /><meta name="ncbi_pagename" content="Hereditary Coproporphyria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hereditary Coproporphyria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hereditary Coproporphyria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/11/08" /><meta name="citation_author" content="Bruce Wang" /><meta name="citation_author" content="D Montgomery Bissell" /><meta name="citation_pmid" content="23236641" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK114807/" /><meta name="citation_keywords" content="Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial" /><meta name="citation_keywords" content="CPOX" /><meta name="citation_keywords" content="Hereditary Coproporphyria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hereditary Coproporphyria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Bruce Wang" /><meta name="DC.Contributor" content="D Montgomery Bissell" /><meta name="DC.Date" content="2018/11/08" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK114807/" /><meta name="description" content="Hereditary coproporphyria (HCP) is an acute (hepatic) porphyria in which the acute symptoms are neurovisceral and occur in discrete episodes. Attacks typically start in the abdomen with low-grade pain that slowly increases over a period of days (not hours) with nausea progressing to vomiting. In some individuals, the pain is predominantly in the back or extremities. When an acute attack is untreated, a motor neuropathy may develop over a period of days or a few weeks. The neuropathy first appears as weakness proximally in the arms and legs, then progresses distally to involve the hands and feet. Some individuals experience respiratory insufficiency due to loss of innervation of the diaphragm and muscles of respiration. Acute attacks are associated commonly with use of certain medications, caloric deprivation, and changes in female reproductive hormones. About 20% of those with an acute attack also experience photosensitivity associated with bullae and skin fragility." /><meta name="og:title" content="Hereditary Coproporphyria" /><meta name="og:type" content="book" /><meta name="og:description" content="Hereditary coproporphyria (HCP) is an acute (hepatic) porphyria in which the acute symptoms are neurovisceral and occur in discrete episodes. Attacks typically start in the abdomen with low-grade pain that slowly increases over a period of days (not hours) with nausea progressing to vomiting. In some individuals, the pain is predominantly in the back or extremities. When an acute attack is untreated, a motor neuropathy may develop over a period of days or a few weeks. The neuropathy first appears as weakness proximally in the arms and legs, then progresses distally to involve the hands and feet. Some individuals experience respiratory insufficiency due to loss of innervation of the diaphragm and muscles of respiration. Acute attacks are associated commonly with use of certain medications, caloric deprivation, and changes in female reproductive hormones. About 20% of those with an acute attack also experience photosensitivity associated with bullae and skin fragility." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK114807/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hcp/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK114807/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C1179E0407E51000000000637022B.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK114807_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK114807_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ataxias/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hgc/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK114807_"><span class="title" itemprop="name">Hereditary Coproporphyria</span></h1><p class="contrib-group"><span itemprop="author">Bruce Wang</span>, MD and <span itemprop="author">D Montgomery Bissell</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK114807_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK114807_ai__"><div class="contrib half_rhythm"><span itemprop="author">Bruce Wang</span>, MD<div class="affiliation small">University of California San Francisco<br />San Francisco, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.fscu@gnaw.ecurb" class="oemail">ude.fscu@gnaw.ecurb</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">D Montgomery Bissell</span>, MD<div class="affiliation small">University of California San Francisco<br />San Francisco, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.fscu@llessib.yremogtnom" class="oemail">ude.fscu@llessib.yremogtnom</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 13, 2012</span>; Last Update: <span itemprop="dateModified">November 8, 2018</span>.</p><p><em>Estimated reading time: 32 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hcp.Summary" itemprop="description"><h2 id="_hcp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hereditary coproporphyria (HCP) is an acute (hepatic) porphyria in which the acute symptoms are neurovisceral and occur in discrete episodes. Attacks typically start in the abdomen with low-grade pain that slowly increases over a period of days (not hours) with nausea progressing to vomiting. In some individuals, the pain is predominantly in the back or extremities. When an acute attack is untreated, a motor neuropathy may develop over a period of days or a few weeks. The neuropathy first appears as weakness proximally in the arms and legs, then progresses distally to involve the hands and feet. Some individuals experience respiratory insufficiency due to loss of innervation of the diaphragm and muscles of respiration. Acute attacks are associated commonly with use of certain medications, caloric deprivation, and changes in female reproductive hormones. About 20% of those with an acute attack also experience photosensitivity associated with bullae and skin fragility.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The most sensitive and specific biochemical screening test for any one of the acute porphyrias (including HCP) during an acute attack is a striking increase in urinary porphobilinogen. Quantitative analysis of porphyrins in both urine and feces is essential to distinguish between the different acute porphyrias and establish the diagnosis of HCP. Identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CPOX</i> (encoding the enzyme coproporphyrinogen-III oxidase) confirms the diagnosis and enables family studies.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Acute attacks are treated by discontinuation of any medications thought to induce attacks, management of dehydration and/or hyponatremia, administration of carbohydrate, and infusion of hematin (Panhematin<sup>&#x000ae;</sup>, Recordati Group). Treatment of symptoms and complications, such as seizures, should be with medications known to be safe in acute porphyria (see <a href="http://www.drugs-porphyria.org" ref="pagearea=abstract&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.drugs-porphyria.org</a>). A minority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals experience repeat acute attacks, in which case management strategies include suppression of ovulation in females, prophylactic use of hematin, and liver transplantation when attacks and neurologic complications persist despite multiple courses of hematin. Treatment of chronic (cutaneous) manifestations is through avoidance of sun/light, including wearing protective clothing and using protective tinted glass for cars and windows to prevent exposure to blue light.</p><p><i>Prevention of primary manifestations:</i> Agents or circumstances that may trigger an acute attack (including use of oral contraception and progestins in women) are avoided. Suppression of menses using a GnRH agonist (leuprolide, nafarelin, and others) may help <i>CPOX</i> heterozygotes who experience monthly exacerbations. Menopausal symptoms may occur as a side effect of GnRH agonists and can be treated with a low dose of estrogen. In <i>CPOX</i> heterozygotes undergoing surgery, minimize preoperative fasting and provide intravenous glucose in the perioperative period. Anesthesia induction using non-barbiturate agents is recommended.</p><p><i>Surveillance</i>: Annual liver and kidney function in those with chronically elevated ALA levels and/or those older than age 60 years; assessment for liver fibrosis (transient elastography [FibroScan<sup>&#x000ae;</sup>] or a blood-based test [FibroTest<sup>&#x000ae;</sup> or FibroSure<sup>&#x000ae;</sup>]); annual screening for hepatocellular carcinoma with abdominal imaging and serum alpha-fetoprotein in those older than age 60.</p><p><i>Agents/circumstances to avoid:</i> Fasting, use of oral contraception and progestins in females, and certain drugs including barbiturates and phenytoin.</p><p><i>Evaluation of relatives at risk:</i> If the family-specific <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is known, clarification of the genetic status of relatives at risk allows early diagnosis of heterozygotes and education regarding how to avoid risk factors known to be associated with acute attacks.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HCP is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner with low <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Most individuals with HCP have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent; the proportion with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown. Each child of an individual with HCP has a 50% chance of inheriting the <i>CPOX</i> pathogenic variant. Because of reduced penetrance, many individuals with a <i>CPOX</i> pathogenic variant have no signs or symptoms of HCP. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in an affected family member is known.</p></div></div><div id="hcp.Diagnosis"><h2 id="_hcp_Diagnosis_">Diagnosis</h2><p>Hereditary coproporphyria (HCP) is classified as both an acute (hepatic) porphyria (with neurologic manifestations that occur as discrete, severe episodes) and a chronic (cutaneous) porphyria with long-standing photosensitivity.</p><p>Diagnostic criteria for HCP have been published [<a class="bk_pop" href="#hcp.REF.anderson.2005.439">Anderson et al 2005</a>, <a class="bk_pop" href="#hcp.REF.whatley.2009.1406">Whatley et al 2009</a>].</p><div id="hcp.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Acute hepatic porphyria <b>should be suspected</b> in individuals with the following symptoms or findings:</p><ul><li class="half_rhythm"><div>Nausea for at least 48 hours</div></li><li class="half_rhythm"><div>Abdominal, back, or extremity pain for at least 48 hours</div></li><li class="half_rhythm"><div>New-onset seizures</div></li><li class="half_rhythm"><div>Hyponatremia</div></li><li class="half_rhythm"><div>Family history of porphyria</div></li></ul><p>Note: (1) Although <i>CPOX</i> pathogenic variants occur equally in males and females, acute attacks are much more frequent in women, mainly between ages 16 and 45 years (the years of active ovulation). (2) Absence of a known family history of porphyria does not preclude the diagnosis.</p><p><b>Chronic cutaneous porphyria is suspected</b> in individuals with bullae and fragility of light-exposed skin that result in depigmented scars; however, the cutaneous signs occur in only a minority of heterozygotes, even during an acute attack.</p></div><div id="hcp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of HCP <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by biochemical testing (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>), followed by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CPOX</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fighcpTmoleculargenetictestingusedin" rid-ob="figobhcpTmoleculargenetictestingusedin">Table 2</a>).</p><div id="hcp.Biochemical_Testing"><h4>Biochemical Testing</h4><p>For an individual with pain and neurologic signs, the initial goal is to determine if the symptoms can be attributed to an attack related to any one of the acute porphyrias (i.e., ALA dehydratase deficiency porphyria, acute intermittent porphyria, hereditary coproporphyria, or variegate porphyria) (see <a href="#hcp.Differential_Diagnosis">Differential Diagnosis</a>). Note: Since initial management is the same for all four types of acute porphyria, it is not necessary to determine at the outset of treatment which one of the four types of acute porphyria is present.</p><p>The most sensitive and specific biochemical diagnostic tests for HCP are detailed in <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>. Once the diagnosis of an acute porphyria is established by identification of a striking increase in urinary porphobilinogen (PBG), quantitative analysis of porphyrins in both urine and feces may help define the specific type (<a class="figpopup" href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-figpopup="fighcpF1" rid-ob="figobhcpF1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="fighcpF1" co-legend-rid="figlgndhcpF1"><a href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fighcpF1" rid-ob="figobhcpF1"><img class="small-thumb" src="/books/NBK114807/bin/hcp-Image001.gif" src-large="/books/NBK114807/bin/hcp-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndhcpF1"><h4 id="hcp.F1"><a href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-ob="figobhcpF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Excretion profile of the hepatic porphyrias Profile of heme precursor excretion for the types of hepatic porphyria. The pathway of heme synthesis (arrows) is served by a series of enzymes (boxes). Pathogenic variants that decrease the function of a particular <a href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-ob="figobhcpF1">(more...)</a></p></div></div><ul><li class="half_rhythm"><div>Active HCP is suggested by a quantitative urinary PBG that is at least threefold the upper limit of normal.</div></li><li class="half_rhythm"><div>The characteristic finding in stool is COPRO &#x0003e;&#x0003e; PROTO, quantified as units/g dry weight of feces. Note: Some laboratories report units/24 hours, which is inherently inaccurate. US laboratories that do the more precise analysis include <a href="http://www.aruplab.com/guides/ug/tests/0099824.jsp" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ARUP</a> (Salt Lake City, UT) and the <a href="http://pmch.utmb.edu/clinics-services/porphyria-center" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria Laboratory, University of Texas Medical Branch</a> (Galveston, TX).</div></li><li class="half_rhythm"><div>The diagnosis is further substantiated by analysis of the COPRO-III/COPRO-I fecal porphyrin ratio, showing that 60%-95% of the total COPRO is isomer-III. In a normal (or "negative") test, the predominant fecal porphyrin is PROTO, and the COPRO isomer III/I ratio in many cases is &#x0003c;0.5 [<a class="bk_pop" href="#hcp.REF.k_hnel.2000.465">K&#x000fc;hnel et al 2000</a>].</div></li></ul><div id="hcp.T.biochemical_characteristics_of_her" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Biochemical Characteristics of Hereditary Coproporphyria (HCP)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.biochemical_characteristics_of_her_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_1" style="text-align:left;vertical-align:middle;">Deficient Enzyme</th><th id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Urine</th><th id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:center;vertical-align:middle;">Stool</th></tr><tr><th headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_2" id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Active</th><th headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_2" id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asx</th><th headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_3" id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Active</th><th headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_3" id="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Asx</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coproporphyringen-III oxidase&#x000a0;<sup>1,&#x000a0;2</sup></td><td headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_2 hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02191;PBG&#x000a0;<sup>3,&#x000a0;4</sup><br />&#x02191;COPRO&#x000a0;<sup>5</sup></td><td headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_2 hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal PBG<br />COPRO&#x000a0;<sup>6</sup></td><td headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_3 hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">COPRO &#x0003e;&#x0003e; PROTO&#x000a0;<sup>7</sup></td><td headers="hd_h_hcp.T.biochemical_characteristics_of_her_1_1_1_3 hd_h_hcp.T.biochemical_characteristics_of_her_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 8</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Active = symptomatic <i>CPOX</i> heterozygotes; Asx = asymptomatic <i>CPOX</i> heterozygotes; COPRO = coproporphyrin; NormaI PBG = &#x0003c;2 mg (0.85 &#x003bc;mol) per g urine creatinine; PBG = porphobilinogen; PROTO = protoporphyrin</p></div></dd><dt>1. </dt><dd><div id="hcp.TF.1.1"><p class="no_margin">Also known as coproporphyrinogen oxidase and coproporphyrinogen decarboxylase</p></div></dd><dt>2. </dt><dd><div id="hcp.TF.1.2"><p class="no_margin">The enzyme assay is not widely available and is not used for diagnostic purposes.</p></div></dd><dt>3. </dt><dd><div id="hcp.TF.1.3"><p class="no_margin">Active HCP is suggested by a quantitative urine PBG that is at least threefold the upper limit of normal.</p></div></dd><dt>4. </dt><dd><div id="hcp.TF.1.4"><p class="no_margin">Commercial laboratories offer quantitative delta aminolevulinic acid (ALA), PBG, and fractionated urine porphyrins. Values normalized to urine creatinine are satisfactory for clinical use, making a 24-hour collection unnecessary.</p></div></dd><dt>5. </dt><dd><div id="hcp.TF.1.5"><p class="no_margin">See <a href="#hcp.Differential_Diagnosis">Differential Diagnosis</a> for discussion of nonspecific elevation of COPRO in the urine.</p></div></dd><dt>6. </dt><dd><div id="hcp.TF.1.6"><p class="no_margin">Fractionated urine porphyrins may reveal a minor rise in COPRO (&#x0003c;3-fold the upper limit of normal); however, this is nonspecific and insufficient for diagnosis (see <a href="#hcp.Differential_Diagnosis">Differential Diagnosis</a>).</p></div></dd><dt>7. </dt><dd><div id="hcp.TF.1.7"><p class="no_margin">60%-95% of the total COPRO is isomer-III.</p></div></dd><dt>8. </dt><dd><div id="hcp.TF.1.8"><p class="no_margin">Fecal porphyrin analysis is the best test for distinguishing HCP from nonspecific coproporphyrinuria: heterozygotes show a predominance of fecal COPRO and an elevated COPRO III/I ratio (see <a href="#hcp.Biochemical_Testing">Biochemical Testing</a>).</p></div></dd></dl></div></div></div></div><div id="hcp.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>The molecular testing approach typically includes <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> targeting the type of acute porphyria suggested by biochemical testing.</p><ul><li class="half_rhythm"><div>Sequence analysis of <i>CPOX</i> is performed first and followed by <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div>If detailed <i>CPOX</i> testing is normal, <i>PPOX</i> (the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> for variegate porphyria [VP]) is analyzed. The biochemical findings in HCP and VP can overlap, leading to misassignment of diagnosis in some instances.</div></li></ul><div id="hcp.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Hereditary Coproporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CPOX</i></td><td headers="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">32/33&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_hcp.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 7</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hcp.TF.2.1"><p class="no_margin">See <a href="/books/NBK114807/#hcp.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hcp.TF.2.2"><p class="no_margin">See <a href="#hcp.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hcp.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hcp.TF.2.4"><p class="no_margin">Sequence analysis identified a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in 31 of 32 (97%) individuals with the clinical and biochemical diagnosis of HCP [<a class="bk_pop" href="#hcp.REF.whatley.2009.1406">Whatley et al 2009</a>].</p></div></dd><dt>5. </dt><dd><div id="hcp.TF.2.5"><p class="no_margin"><a class="bk_pop" href="#hcp.REF.grimes.2016.2142">Grimes et al [2016]</a>, <a class="bk_pop" href="#hcp.REF.lambie.2018.616">Lambie et al [2018]</a></p></div></dd><dt>6. </dt><dd><div id="hcp.TF.2.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="hcp.TF.2.7"><p class="no_margin">A 13-kb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> extending from <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 to the 3'UTR [<a class="bk_pop" href="#hcp.REF.whatley.2009.1406">Whatley et al 2009</a>] and a 1.3-kb deletion spanning exon 5 (found in 4 Swedish families) [<a class="bk_pop" href="#hcp.REF.barbaro.2012.249">Barbaro et al 2012</a>] have been published.</p></div></dd></dl></div></div></div></div></div></div><div id="hcp.Clinical_Characteristics"><h2 id="_hcp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hcp.Clinical_Description"><h3>Clinical Description</h3><p>Hereditary coproporphyria (HCP) is classified as both an acute and a chronic porphyria. Porphyrias with neurologic manifestations are considered acute, because the symptoms occur as discrete, severe episodes. Porphyrias with cutaneous manifestations are considered chronic, because photosensitivity is long standing (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.classification_of_the_hereditary_p/?report=objectonly" target="object" rid-figpopup="fighcpTclassificationofthehereditaryp" rid-ob="figobhcpTclassificationofthehereditaryp">Table 3</a>).</p><p>In a German study of 46 individuals with acute HCP, 90% had abdominal pain; only 13% had cutaneous findings despite substantial overproduction of coproporphyrin [<a class="bk_pop" href="#hcp.REF.k_hnel.2000.465">K&#x000fc;hnel et al 2000</a>]. An earlier British study of 111 individuals with HCP reported similar findings [<a class="bk_pop" href="#hcp.REF.brodie.1977.229">Brodie et al 1977</a>].</p><p>Symptoms prior to puberty in individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> have never been observed.</p><p>Fertility and longevity do not appear to be reduced in <i>CPOX</i> heterozygotes.</p><div id="hcp.Acute_Attacks"><h4>Acute Attacks</h4><p>The initial symptoms of an acute attack are nonspecific, consisting of low-grade abdominal pain that slowly increases over a period of days (not hours) with nausea progressing to vomiting of all oral intake.</p><p>Typically the pain is not well localized but in some instances does mimic acute inflammation of the gallbladder, appendix, or other intra-abdominal organ. In most instances the abdominal examination is unremarkable except for diminished bowel sounds consistent with ileus, which is common and can be seen on abdominal radiography. Typically fever is absent. In a young woman of reproductive age, the symptoms may raise the question of early pregnancy.</p><p>Prior to the widespread use of abdominal imaging in the emergency room setting, some individuals with abdominal pain and undiagnosed acute porphyria underwent urgent exploratory surgery. Thus, a history of abdominal surgery with negative findings was considered characteristic of acute porphyria.</p><p>A minority of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals has predominantly back or extremity pain, which is usually deep and aching, not localized to joints or muscle groups.</p><p><b>Neurologic manifestations.</b> Seizures may occur early in an attack and be the problem that brings the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to medical attention. In a young woman with abdominal pain and new-onset seizures, it is critical to consider acute porphyria because of the implications for seizure management (see <a href="#hcp.Management">Management</a>).</p><p>When an attack is unrecognized as such or treated with inappropriate medications, it may progress to a motor neuropathy, which typically occurs many days to a few weeks after the onset of symptoms. The neuropathy first appears as weakness proximally in the arms and legs, then progresses distally to involve the hands and feet. Neurosensory function remains largely intact.</p><p>In some individuals the motor neuropathy eventually involves nerves serving the diaphragm and muscles of respiration. Ventilator support may be needed.</p><p>Tachycardia and bowel dysmotility (manifest as constipation) are common in acute attacks and believed to represent involvement of the autonomic nervous system.</p><p>Of note, when the acute attack is recognized early and treated appropriately (see <a href="#hcp.Management">Management</a>), the outlook for survival and eventual complete recovery is good.</p><p><b>Psychosis.</b> The mental status of people presenting with an acute attack of porphyria varies widely and can include psychosis. Commonly the predominant feature is distress (including pain) that may seem hysterical or feigned, given a negative examination, absence of fever, and abdominal imaging showing some ileus only. Incessant demands for relief may be interpreted as drug-seeking behavior.</p><p>Because of the altered affect in acute porphyria, it has been speculated that mental illness is a long-term consequence of an attack and that mental institutions may house disproportionately large numbers of individuals with undiagnosed acute porphyria. Screening of residents in mental health facilities by urinary PBG and/or PBG deaminase activity in blood (which diagnoses <a href="/books/n/gene/aip/">acute intermittent porphyria</a>) has been performed, with mixed results [<a class="bk_pop" href="#hcp.REF.jaraprado.2000.404">Jara-Prado et al 2000</a>]. The experience of those who have monitored <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals over many years suggests that heterozygotes who are at risk for one of the acute porphyrias are no more prone to chronic mental illness than individuals in the general population; however, a prospective study is needed.</p><p><b>Kidney and liver disease.</b> In people with any type of acute porphyria, the kidneys and liver may develop chronic changes that often are subclinical. One manifestation of the liver problem is excess primary liver cancer (hepatocellular carcinoma). The risk is greatest in women older than age 60 with acute intermittent porphyria (160-fold increased risk above the general population risk); for men there is a 37-fold increase in risk [<a class="bk_pop" href="#hcp.REF.sardh.2013.1063">Sardh et al 2013</a>]. This and the kidney disease may be restricted largely to heterozygotes with chronically elevated plasma or urine delta aminolevulinic acid (ALA). Hypertension may be chronic in those with frequent symptoms and may contribute to renal disease.</p><p>Inasmuch as ALA and porphobilinogen (PBG) tend to be minimally elevated or normal in HCP heterozygotes, the risk of hepatic and renal complications may be less in HCP than in <a href="/books/n/gene/aip/">acute intermittent porphyria</a>.</p><p><b>Circumstances commonly associated with acute attacks</b> are caloric deprivation, changes in female reproductive hormones, and use of porphyria-inducing medications or drugs:</p><ul><li class="half_rhythm"><div><b>Caloric deprivation.</b> Fasting appears to sensitize the heme-synthetic pathway to an inducer, which could be external (i.e., a medication) or internal (ovarian hormones). The sensitizing effect of caloric deprivation was demonstrated in the 1960s in experimental animals and has been confirmed by clinical observation. People who fail to eat because of intercurrent illness or who undertake drastic weight loss are predisposed to an acute attack. First attacks have been reported after reduction gastroplasty for obesity [<a class="bk_pop" href="#hcp.REF.bonkovsky.2008.2813">Bonkovsky et al 2008</a>]. <i>CPOX</i> heterozygotes undergoing surgery are at risk because of the routine preoperative fast. This and other anecdotal experience have led to consensus that the first line of treatment for an acute attack is intravenous glucose, which is occasionally helpful.</div></li><li class="half_rhythm"><div><b>Changes in female reproductive hormones.</b> A role for female reproductive hormones can be inferred from the fact that acute attacks are infrequent prior to menarche and after menopause. Some women have monthly attacks that appear a few days before the onset of menstruation (when progestins peak). Attacks have been linked to use of oral contraceptives; the risk may be associated more with the progesterone component than the estrogen component.</div></li><li class="half_rhythm"><div><b>Use of porphyria-inducing medications or drugs.</b> See Management, <a href="#hcp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>.</div></li></ul><p><b>Chronic (cutaneous) manifestations.</b> Photocutaneous damage is present in only a small minority of those with acute attacks. Bullae and fragility of light-exposed skin, in particular the backs of the hands, result in depigmented scars. Facial skin damage also occurs, with excess hair growth on the temples, ears, and cheeks; this is more noticeable in women than in men.</p><p>The cutaneous findings in HCP resemble those in porphyria cutanea tarda (PCT) and in variegate porphyria (VP).</p></div><div id="hcp.Threshold_for_a_Pathogenic_Effect_of"><h4>Threshold for a Pathogenic Effect of Porphyrins and Their Precursors</h4><p>Clinically active acute porphyria is associated with substantial elevation of the precursors ALA and PBG in the blood and urine; the cutaneous porphyrias are associated with increased porphyrins in blood, urine, and feces. In the acute porphyrias and cutaneous porphyrias, a threshold for symptoms appears to exist.</p><ul><li class="half_rhythm"><div><b>Acute (hepatic) porphyrias.</b> A threshold for acute attacks is suggested by the fact that in virtually all symptomatic individuals, urinary PBG excretion exceeds 25 mg/g creatinine, or more than tenfold the upper limit of normal. Urinary ALA excretion increases roughly in parallel.</div></li><li class="half_rhythm"><div>In contrast, in asymptomatic individuals the baseline urinary PBG excretion varies widely, usually low or normal but occasionally exceeding 25 mg/g creatinine. For this reason, it is advisable to establish the baseline urinary PBG excretion for <i>CPOX</i> heterozygotes (see Management, <a href="#hcp.Evaluations_Following_Initial_Diagno">Evaluations Following Initial Diagnosis</a>).</div></li><li class="half_rhythm"><div><b>Chronic (cutaneous) porphyrias.</b> A threshold has been well defined for porphyria cutanea tarda (PCT), in which photosensitivity occurs at values of urine uroporphyrin (the predominant pathway intermediate) that are more than 20-fold the upper limit of normal. However, the same is not apparent with regard to urine coproporphyrin: only a minority of <i>CPOX</i> heterozygotes exhibit any photosensitivity.</div></li></ul><p>Of note, in individuals with HCP and chronic liver disease the cutaneous component may be more prominent than expected for the observed urine or plasma PBG concentration. Coproporphyrin leaves the plasma largely via the liver going into bile. In chronic liver disease, bile transport processes or bile formation may be impaired, leading to accumulation of coproporphyrin in plasma, which then results in photosensitivity.</p></div></div><div id="hcp.Pathophysiology"><h3>Pathophysiology</h3><p>The regulation of heme synthesis differs in liver and in bone marrow, the principal sites of heme production in the body. The liver is the main source of precursors in the acute (hepatic) porphyrias: acute attacks are precipitated when environmental factors stimulate increased hepatic heme synthesis and the genetically altered step in heme production becomes rate limiting (<a class="figpopup" href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-figpopup="fighcpF1" rid-ob="figobhcpF1">Figure 1</a>). Heme synthesis in the liver largely serves production of the cytochrome P450 family of heme-proteins, which are present in high concentration in the liver and have a relatively high turnover rate.</p><p>It is estimated that 20%-25% of total heme production normally occurs in the liver [<a class="bk_pop" href="#hcp.REF.billing.1978.481">Billing 1978</a>]; however, that proportion increases when the liver is exposed to xenobiotics that undergo oxidative metabolism and stimulate cytochrome production (especially CYP3A4).</p><p><b>Acute attacks.</b> The precursors ALA and PBG, unlike porphyrins, are colorless and non-fluorescent and do not contribute to photosensitivity in porphyria. Rather, ALA and PBG are highly associated with the neurologic manifestations of acute porphyria and are probably causal, although the mechanism remains speculative. The currently favored hypothesis implicates ALA (more than PBG), in part because acute neurologic symptoms occur in two other inherited conditions involving overproduction of ALA but not PBG (delta ALA dehydratase deficiency porphyria and <a href="/books/n/gene/tyrosinemia/">tyrosinemia</a>). In addition, lead poisoning causes a similar biochemical derangement by binding the sulfhydryls of ALA dehydratase and reducing enzymatic activity; the symptoms in lead poisoning closely mimic those of acute porphyria [<a class="bk_pop" href="#hcp.REF.bissell.2015.313">Bissell et al 2015</a>]. Experimental studies indicate that ALA is a pro-oxidant species that is capable of damaging the inner membrane of mitochondria [<a class="bk_pop" href="#hcp.REF.vercesi.1994.86">Vercesi et al 1994</a>].</p><p>Liver transplantation has established that this organ is responsible for acute attacks. Liver transplantation has cured individuals with refractory acute symptoms [<a class="bk_pop" href="#hcp.REF.soonawalla.2004.705">Soonawalla et al 2004</a>]. Moreover, transplantation of a porphyric liver into a normal recipient in two cases resulted in high circulating levels of ALA and PBG and symptoms of porphyria [<a class="bk_pop" href="#hcp.REF.dowman.2011.571">Dowman et al 2011</a>].</p><p><b>Cutaneous manifestations.</b> Porphyrins are energized by blue light (peak wavelength 410 nm). In a test tube, as activated porphyrins relax back to the ground state, the released energy is evident as red fluorescence (ca. 625 nm). In vivo, the cycle of light activation and relaxation back to the ground state causes tissue damage, the nature of which varies with the porphyrin. URO and COPRO give rise to bullae and fragility of light-exposed skin, in particular the backs of the hands.</p></div><div id="hcp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p><b>HCP.</b>
<i>CPOX</i> pathogenic variants are not clustered around the enzymatic site. Furthermore, no correlation exists between the clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and the residual enzymatic activity measured in vitro for a given <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#hcp.REF.lamoril.2001.1130">Lamoril et al 2001</a>].</p><ul><li class="half_rhythm"><div><b>Neonatal-onset HCP.</b> In two reported cases, <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> (but not <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>) <i>CPOX</i> variants have been associated with massive elevation of coproporphyrins, cutaneous blistering, and hemolytic anemia with onset in the neonatal period. In one case, the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6 causing exon 6 skipping. In the other, it was a four-base-pair <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> in exon 7. The clinical picture resembled harderporphyria (see <a href="#hcp.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>), but fecal analysis indicated HCP (markedly increased coproporphyrin and normal harderoporphyrin). Both cases also manifested adrenal insufficiency and hypospadias (with a 46,XY <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a>) [<a class="bk_pop" href="#hcp.REF.hasegawa.2017.99">Hasegawa et al 2017</a>]. The syndrome has been termed "neonatal-onset HCP," although the same <i>CPOX</i> variants also give rise to typical adult-onset HCP. The reason for the dramatic difference in presentation is unknown. It has been suggested that adrenal insufficiency is the proximal cause of the neonatal form, perhaps because heme synthesis is regulated by adrenal steroids to a degree that has not been appreciated.</div></li><li class="half_rhythm"><div><b>Homozygotes for <i>CPOX</i> pathogenic variants</b> that cause minimal or no symptoms in heterozygotes have very low coproporphyringen-III oxidase activity and a severe <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#hcp.REF.schmitt.2005.3089">Schmitt et al 2005</a>, <a class="bk_pop" href="#hcp.REF.hasanoglu.2011.225">Hasanoglu et al 2011</a>] (see <a href="#hcp.Genetically_Related_Allelic_Disorder">Genetically Related Disorders</a>).</div></li></ul><p><b>Double heterozygosity for pathogenic variants in genes causing two different types of acute (hepatic) porphyria.</b> Double heterozygotes for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CPOX</i> and either a pathogenic variant in <i>PPOX</i> (<a href="/books/n/gene/porphyria-var/">variegate porphyria</a> [VP]) [<a class="bk_pop" href="#hcp.REF.van_tuyll_van_serooskerken.2011.2249">van Tuyll van Serooskerken et al 2011</a>] or <i>ALAD</i> (ALA dehydratase deficiency porphyria [ADP]) [<a class="bk_pop" href="#hcp.REF.akagi.2006.237">Akagi et al 2006</a>] have been described. The phenotypes of such double heterozygotes vary but are not necessarily more severe than those associated with heterozygosity for either pathogenic variant alone, suggesting that double heterozygotes for two different types of acute porphyria may not be as rare as has been assumed.</p></div><div id="hcp.Penetrance"><h3>Penetrance</h3><p>Because population studies to determine the prevalence of HCP heterozygosity have not been done, the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of <i>CPOX</i> pathogenic variants is unknown. Given the rarity of acute attacks of HCP relative to <a href="/books/n/gene/aip/">acute intermittent porphyria</a> (AIP), it is suspected that only a small minority of <i>CPOX</i> heterozygotes express the clinical disease. In 32 members of an Australian family, 14 (including 10 adults) were determined to have HCP on the basis of a high fecal COPRO III/I ratio and/or low lymphocyte CPOX enzyme activity; however, only one had clinical symptoms of porphyria [<a class="bk_pop" href="#hcp.REF.blake.1992.96">Blake et al 1992</a>].</p><p>HCP, along with AIP and VP, are genetic disorders with reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Heme production in most heterozygotes appears to be adequate for physiologic homeostasis. Thus, environmental or physiologic factors play a role in the pathogenesis of acute attacks (see Management, <a href="#hcp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>). Genetic co-factors may also be involved; none has been identified to date.</p></div><div id="hcp.Nomenclature"><h3>Nomenclature</h3><p>"Coproporphyrinuria" describes urine with an elevated level of coproporphyrin of any cause.</p><p>Coproporphyria in individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is referred to as hereditary coproporphyria.</p></div><div id="hcp.Prevalence"><h3>Prevalence</h3><p>Clinical experience suggests that HCP is the least prevalent of the three principal types of acute porphyria: AIP, VP, and HCP. However, symptoms in HCP may be less frequent than in AIP or VP. Population surveys for <i>CPOX</i> pathogenic variants have not been reported.</p></div></div><div id="hcp.Genetically_Related_Allelic_Disorder"><h2 id="_hcp_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p><b>Biallelic <i>CPOX</i> pathogenic variants.</b> Certain <i>CPOX</i> pathogenic variants (notably D400-K404 in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 6) in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state result in a disorder called harderoporphyria [<a class="bk_pop" href="#hcp.REF.hasanoglu.2011.225">Hasanoglu et al 2011</a>]. Some pathogenic variants may affect the active site of the enzyme, possibly causing premature separation of CPOX from its substrate. The result is incomplete decarboxylation of COPROgen, yielding the tricarboxylic intermediate harderoporphyrinogen instead of dicarboxylic PROTOgen (<a class="figpopup" href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-figpopup="fighcpF1" rid-ob="figobhcpF1">Figure 1</a>).</p><p>Heterozygotes for a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that is associated with harderoporphyria have no symptoms; those with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants have large amounts of harderoporphyrin in the stool and neonatal onset of hemolytic anemia and jaundice, which can resemble <a href="/books/n/gene/cep/">congenital erythropoietic porphyria</a>, an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> condition with hemolysis and severe photosensitivity in infancy. They can also have acute porphyric attacks with high levels of urinary ALA and PBG. One infant died at age five months, apparently from complications of an acute attack [<a class="bk_pop" href="#hcp.REF.hasanoglu.2011.225">Hasanoglu et al 2011</a>]. Some develop normally while others exhibit short stature.</p></div><div id="hcp.Differential_Diagnosis"><h2 id="_hcp_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>The genetic porphyrias</b> comprise a group of distinct diseases, each resulting from alteration of a specific step in the heme synthesis pathway that results in accumulation of a specific metabolite (<a class="figpopup" href="/books/NBK114807/figure/hcp.F1/?report=objectonly" target="object" rid-figpopup="fighcpF1" rid-ob="figobhcpF1">Figure 1</a>).</p><p>In <a class="figpopup" href="/books/NBK114807/table/hcp.T.classification_of_the_hereditary_p/?report=objectonly" target="object" rid-figpopup="fighcpTclassificationofthehereditaryp" rid-ob="figobhcpTclassificationofthehereditaryp">Table 3</a> the porphyrias are grouped by their principal clinical manifestations (neurovisceral or cutaneous) and the tissue origin of the excess production of pathway intermediates (liver [i.e., hepatic] or bone marrow [i.e., erythropoietic]).</p><ul><li class="half_rhythm"><div>Porphyrias with neurovisceral manifestations are considered acute because the symptoms occur as discrete, severe episodes, which may be spontaneous but frequently are induced by external factors. The four acute porphyrias are: ALA dehydratase-deficiency porphyria (ADP), <a href="/books/n/gene/aip/">acute intermittent porphyria</a> (AIP), HCP, and <a href="/books/n/gene/porphyria-var/">variegate porphyria</a> (VP). Only a few individuals with ADP have been reported in the world literature.</div></li><li class="half_rhythm"><div>Porphyrias with cutaneous manifestations include either chronic blistering skin lesions (i.e., VP as well as PCT, HCP, CEP, and <a href="/books/n/gene/hep/">hepatoerythropoietic porphyria</a> [HEP]) or acute non-blistering photosensitivity (i.e., <a href="/books/n/gene/epp-ar/">EPP</a> and <a href="/books/n/gene/epp-xl/">XLP</a>).</div></li></ul><div id="hcp.T.classification_of_the_hereditary_p" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Classification of the Hereditary Porphyrias</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.classification_of_the_hereditary_p/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.classification_of_the_hereditary_p_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" rowspan="2" colspan="2" scope="colgroup" headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" style="text-align:left;vertical-align:middle;">Type of Porphyria</th><th id="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Findings</th><th id="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th></tr><tr><th headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2" id="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Neurovisceral&#x000a0;<sup>1</sup></th><th headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2" id="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Photocutaneous</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hepatic</b></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">ADP</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/aip/">AIP</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">HCP</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-ct/">PCT type II</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/porphyria-var/">VP</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Erythropoietic</b></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cep/">CEP</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/epp-ar/">EPP, AR</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+&#x000a0;<sup>2</sup></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/epp-xl/">XLP</a></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0</td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_2 hd_h_hcp.T.classification_of_the_hereditary_p_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">+&#x000a0;<sup>2</sup></td><td headers="hd_h_hcp.T.classification_of_the_hereditary_p_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">0 = no symptoms; + = mild to severe symptoms; AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; ADP = ALA dehydratase-deficiency porphyria; AIP = acute intermittent porphyria; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; CEP = <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> erythropoietic porphyria; EPP = erythropoietic protoporphyria; HCP = hereditary coproporphyria; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; PCT = porphyria cutanea tarda; VP = variegate porphyria; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a>; XLP = X-Linked protoporphyria</p></div></dd><dt>1. </dt><dd><div id="hcp.TF.3.1"><p class="no_margin">Porphyrias with neurovisceral manifestations have been considered "acute" in part because the most common of these disorders, named "acute intermittent porphyria," is the prototype for the neurovisceral porphyrias in which symptoms can occur acutely as discrete, severe episodes; however, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop chronic manifestations, and a few remain susceptible to exacerbating factors throughout their lives.</p></div></dd><dt>2. </dt><dd><div id="hcp.TF.3.2"><p class="no_margin">Photocutaneous manifestations of EPP are acute and non-blistering, in contrast to the chronic blistering in the other cutaneous porphyrias (including VP).</p></div></dd></dl></div></div></div><p>While these clinical distinctions are important for the differential diagnosis, biochemical analysis is always necessary; however, biochemical testing may fail to distinguish HCP from VP, in which case <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>CPOX</i> (HCP) and <i>PPOX</i> (VP) may be the only definitive diagnostic test.</p><p>In individuals with progressive weakness due to the motor neuropathy caused by one of the acute porphyrias (AIP, VP, HCP, and ADP), the entity most likely to be considered is acute ascending polyneuropathy, the <b>Guillain-Barr&#x000e9; syndrome</b>. However, abdominal pain, constipation, and tachycardia precede the acute neurologic illness in the acute porphyrias but not in Guillain-Barr&#x000e9; syndrome. CSF protein is normal in the acute porphyrias, but elevated in Guillain-Barr&#x000e9; syndrome. Urinary PBG is markedly elevated in the acute porphyrias when symptoms are present, but normal in Guillain-Barr&#x000e9; syndrome.</p><p><b>Coproporphyrinuria</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Lead intoxication.</b> The predominant elevation of coproporphyrin that is characteristic of HCP can also be seen in lead intoxication, in which the symptoms resemble those of an acute porphyria. The additional diagnostic finding in heavy metal poisoning is elevation of ALA unaccompanied by any increase in PBG.</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/rotor/"><b>Rotor syndrome</b></a><b>,</b> inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner and caused by simultaneous deficiencies of the organic anion transporting polypeptides OATP1B1 and OATP1B3, is also associated with coproporphyrinuria [<a class="bk_pop" href="#hcp.REF.van_de_steeg.2012.519">van de Steeg et al 2012</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Nonspecific coproporphyrinuria.</b> The most important differential diagnosis in an individual with elevated urine coproporphyrin is HCP vs nonspecific coproporphyrinuria. Of all the people referred to a porphyria center, the largest subgroup has nonspecific coproporphyrinuria. Elevation of urine coproporphyrin is associated with a wide range of clinical conditions. It is particularly frequent in acquired liver disease (e.g., chronic viral hepatitis), but can also be seen in neurologic or hematologic diseases. Rarely, it is caused by an inherited hepatic transporter defect.</div><div class="half_rhythm">Two tests helpful for the differential diagnosis of coproporphyrinuria are:</div><ul><li class="half_rhythm"><div>Urine PBG, which is more than tenfold elevated in the inherited acute porphyrias with active symptoms;</div></li><li class="half_rhythm"><div>The ratio of copro-III to copro-I in feces as measured by high-performance liquid chromatography (used for fecal porphyrin fractionation in most commercial labs). In nonspecific coproporphyrinuria the ratio is usually similar to that in normal controls [<a class="bk_pop" href="#hcp.REF.gibson.2000.192">Gibson et al 2000</a>].</div></li></ul><div class="half_rhythm">For a case example of misdiagnosis of nonspecific coproporphyrinuria, click <a href="/books/NBK114807/bin/hcp-Misdiagnosis.pdf">here</a>.</div></li></ul></div><div id="hcp.Management"><h2 id="_hcp_Management_">Management</h2><div id="hcp.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with hereditary coproporphyria (HCP), the evaluations listed in <a class="figpopup" href="/books/NBK114807/table/hcp.T.recommended_evaluations_following/?report=objectonly" target="object" rid-figpopup="fighcpTrecommendedevaluationsfollowing" rid-ob="figobhcpTrecommendedevaluationsfollowing">Table 4</a> are recommended (if they have not already been completed).</p><div id="hcp.T.recommended_evaluations_following" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis of Hereditary Coproporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.recommended_evaluations_following/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.recommended_evaluations_following_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evaluation</th><th id="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review of medications for those thought to induce attacks</td><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#hcp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>.</td></tr><tr><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Detailed neurologic examination</td><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><ul><li class="half_rhythm"><div>For signs of motor neuropathy (indicating a more advanced attack &#x00026; thus, need for early treatment w/hematin; see <a class="figpopup" href="/books/NBK114807/table/hcp.T.treatment_of_acute_attacks_in_indi/?report=objectonly" target="object" rid-figpopup="fighcpTtreatmentofacuteattacksinindi" rid-ob="figobhcpTtreatmentofacuteattacksinindi">Table 5</a>)</div></li><li class="half_rhythm"><div>Inquiry into possibility of seizures&#x000a0;<sup>1</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Measurement of serum sodium concentration</td><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hyponatremia is characteristic &#x00026; may be profound (serum sodium concentration &#x0003c;110 mEq/L), requiring urgent correction w/due regard for risk of central pontine myelinolysis.</td></tr><tr><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Quantitation of urinary excretion of PBG on several occasions over a few mos to establish baseline</td><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For future use in determining if a new symptom or drug reaction is due to an acute attack&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Consultation w/medical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_hcp.T.recommended_evaluations_following_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">PBG = porphobilinogen</p></div></dd><dt>1. </dt><dd><div id="hcp.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#hcp.REF.tran.2013.116">Tran et al [2013]</a></p></div></dd><dt>2. </dt><dd><div id="hcp.TF.4.2"><p class="no_margin">In an acute attack urinary excretion of PBG is substantially elevated over the baseline.</p></div></dd></dl></div></div></div></div><div id="hcp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment guidelines for hereditary coproporphyria have been published [<a class="bk_pop" href="#hcp.REF.balwani.2017.1314">Balwani et al 2017</a>] (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605422/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><div id="hcp.Acute_Attacks_1"><h4>Acute Attacks</h4><div id="hcp.T.treatment_of_acute_attacks_in_indi" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Treatment of Acute Attacks in Individuals with Hereditary Coproporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.treatment_of_acute_attacks_in_indi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.treatment_of_acute_attacks_in_indi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Manifestation</th><th id="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Acute abdominal pain</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Identify &#x00026; discontinue any medications thought to induce attacks.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#hcp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>.</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Discontinue all nonessential medications.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treat symptoms &#x00026; complications w/medications known to be safe in acute porphyria (see <a href="http://www.drugs-porphyria.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www<wbr style="display:inline-block"></wbr>​.drugs-porphyria.org</a>).</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Nausea/vomiting</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Administer glucose-containing IV solution to reverse fasting state.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Some individuals recover w/rehydration &#x00026; glucose infusion only; those who do not respond in 24-48 hours should receive intravenous hematin.</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Obtain a serum sodium level.&#x000a0;<sup>1</sup></td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In those w/hyponatremia, rehydration w/10% dextrose in 0.5N sodium chloride is recommended.&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate to severe acute attacks</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Administer intravenous hematin.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>For use in any attack that requires hospitalization. For those w/a confirmed diagnosis &#x00026; recurrent attacks, hematin is given as soon as it can be obtained, in addition to IV fluids &#x00026; glucose.</div></li><li class="half_rhythm"><div>Hematin is not stocked by most hospital pharmacies but can be obtained by overnight express from the manufacturer (Panhematin<sup>&#x000ae;</sup>, Recordati, 1-888-575-8344).&#x000a0;<sup>3,&#x000a0;4,&#x000a0;5, 6</sup></div></li><li class="half_rhythm"><div>Responses to hematin infusion can include: &#x02193; urine concentration of PBG (the 1st sign) after 2 doses; clinical improvement after 3-4 doses (typically dramatic) w/no further need of narcotic analgesia.</div></li></ul>
</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Motor neuropathy</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Administer hematin as soon as possible if signs of motor neuropathy are present.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hematin given at the initial signs of motor neuropathy may halt its progression; however, it has no effect on established motor deficits, which are the result of axonal degeneration.&#x000a0;<sup>7</sup></td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizures</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Administer short-acting benzodiazepine (e.g., midazolam) or magnesium.&#x000a0;<sup>8</sup></td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">A number of commonly used anti-seizure medications, incl phenytoin &#x00026; sodium valproate, are contraindicated because of the risk of exacerbating an attack.</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Status epilepticus or refractory seizures</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider propofol.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For more prolonged control of seizures, the combination of gabapentin &#x00026; propofol is effective &#x00026; safe.</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Repeat acute attacks &#x00026;/or severe disease</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Suppress ovulation in females.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Use a GnRH agonist (leuprolide, nafarelin, others).&#x000a0;<sup>9</sup></td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Use hematin prophylactically.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chronic use of hematin can lead to iron overload.&#x000a0;<sup>10,&#x000a0;11,&#x000a0;12,&#x000a0;13</sup></td></tr><tr><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consider liver transplantation in selected cases.</td><td headers="hd_h_hcp.T.treatment_of_acute_attacks_in_indi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>The status of the disease in candidates for liver transplantation must be well documented biochemically.</div></li><li class="half_rhythm"><div>Candidates must not have responded to multiple courses of hematin &#x00026; must demonstrate neurologic complication.</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hcp.TF.5.1"><p class="no_margin">Hyponatremia is characteristic and may be profound (serum sodium concentration &#x0003c;110 mEq/L), requiring urgent correction with due regard for the risk of central pontine myelinolysis.</p></div></dd><dt>2. </dt><dd><div id="hcp.TF.5.2"><p class="no_margin">Aggressive administration of dextrose in water may cause the serum sodium concentration to drop to a critically low level.</p></div></dd><dt>3. </dt><dd><div id="hcp.TF.5.3"><p class="no_margin">Hematin (350-mg vial) is reconstituted at the bedside as described in the package insert. Human albumin may be used in place of water (147 mL of a 25% albumin solution) to reduce the risk of a chemical phlebitis, which is the main side effect of hematin administration [<a class="bk_pop" href="#hcp.REF.anderson.2006.537">Anderson et al 2006</a>].</p></div></dd><dt>4. </dt><dd><div id="hcp.TF.5.4"><p class="no_margin">The infusion is started without delay, as hematin in solution decays rapidly [<a class="bk_pop" href="#hcp.REF.goetsch.1986.235">Goetsch &#x00026; Bissell 1986</a>].</p></div></dd><dt>5. </dt><dd><div id="hcp.TF.5.5"><p class="no_margin">The preparation is given into a large peripheral vein or via central line over 10-15 minutes to minimize the risk of phlebitis. The dose is weight based at 3-4 mg/kg; 200 mg once daily is appropriate for most individuals.</p></div></dd><dt>6. </dt><dd><div id="hcp.TF.5.6"><p class="no_margin">An alternative in Europe and elsewhere is heme arginate (Normosang<sup>&#x000ae;</sup>; not available in the US).</p></div></dd><dt>7. </dt><dd><div id="hcp.TF.5.7"><p class="no_margin">Return of function requires axonal regeneration and takes many months. Although it can be complete, some individuals have residual wrist drop or foot drop.</p></div></dd><dt>8. </dt><dd><div id="hcp.TF.5.8"><p class="no_margin">This treatment has been used to control eclamptic seizures [<a class="bk_pop" href="#hcp.REF.sadeh.1991.712">Sadeh et al 1991</a>].</p></div></dd><dt>9. </dt><dd><div id="hcp.TF.5.9"><p class="no_margin">Oral contraceptives and progestins should be avoided.</p></div></dd><dt>10. </dt><dd><div id="hcp.TF.5.10"><p class="no_margin">Treatment of iron overload is indicated when the serum ferritin exceeds 1,500 ng/mL.</p></div></dd><dt>11. </dt><dd><div id="hcp.TF.5.11"><p class="no_margin">An oral chelator, such as deferasirox or deferiprone, is convenient but causes side effects of gastric distress and nausea in some users.</p></div></dd><dt>12. </dt><dd><div id="hcp.TF.5.12"><p class="no_margin">A small phlebotomy can be done with each hematin infusion, provided the hemoglobin is &#x0003e;10 g/dL. Withdrawal of 100 mL of blood is sufficient for maintaining iron balance, relative to the amount of iron in a 250-mg dose of injectable hematin.</p></div></dd><dt>13. </dt><dd><div id="hcp.TF.5.13"><p class="no_margin">For those with a significant iron burden, withdrawal of 200 cc of blood with each hematin infusion will produce net negative iron balance.</p></div></dd></dl></div></div></div></div><div id="hcp.Chronic_Cutaneous_Manifestations"><h4>Chronic (Cutaneous) Manifestations</h4><div id="hcp.T.treatment_of_lowgrade_chronic_or_s" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Treatment of Low-Grade Chronic or Seasonal Cutaneous Symptoms in Individuals with Hereditary Coproporphyria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.treatment_of_lowgrade_chronic_or_s/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.treatment_of_lowgrade_chronic_or_s_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoid sun/light.</td><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">This includes both direct sun/light &#x00026; through window glass.&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Wear protective clothing: long sleeves, gloves, &#x00026; wide-brimmed hats.</td><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Topical sunscreens are not helpful because they block UVB light, not the blue light that causes porphyrin-related skin injury.</td></tr><tr><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Use protective tinted glass for cars &#x00026; windows to prevent exposure to blue light.</td><td headers="hd_h_hcp.T.treatment_of_lowgrade_chronic_or_s_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gray or smoke-colored filters provide only partial protection.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hcp.TF.6.1"><p class="no_margin">Damage is caused by blue light and long-wave ultraviolet light (UVA), both of which pass through window glass.</p></div></dd></dl></div></div></div><p>Note: The association of cutaneous manifestations with severe attacks (in which porphyrins as well as ALA and PBG are markedly increased) suggests that the cutaneous as well as the neurovisceral symptoms could respond to hematin administration. Indeed, this is the finding of a case report of an individual with severe HCP who was given "maintenance" hematin [<a class="bk_pop" href="#hcp.REF.ma.2011.135">Ma et al 2011</a>].</p></div></div><div id="hcp.Prevention_of_Primary_Manifestations"><h3>Prevention of Primary Manifestations</h3><div id="hcp.T.prevention_of_acute_attacks_in_cop" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Prevention of Acute Attacks in <i>COPX</i> Heterozygotes</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.T.prevention_of_acute_attacks_in_cop/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.T.prevention_of_acute_attacks_in_cop_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Principle</th><th id="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prevention</th><th id="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Consideration/Other</th></tr></thead><tbody><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Identifying those at risk of attacks</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#hcp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a>.</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Education of at-risk individuals</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Educate regarding circumstances that may trigger an acute attack (see <a href="#hcp.Acute_Attacks">Clinical Description</a>).</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Selection of appropriate contraception for females</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">The recommended method of birth control for HCP heterozygotes is an IUD plus a barrier (diaphragm &#x00026;/or condom).&#x000a0;<sup>1</sup></td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>A copper-eluting IUD is theoretically the safest in women w/porphyria.</div></li><li class="half_rhythm"><div>The hormone-eluting IUD may also be safe because the systemic increase in hormone is quite small; however, little information exists on its use in women w/acute porphyria.</div></li></ul>
</td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Suppress menses using a GnRH agonist.</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Leuprolide, nafarelin, &#x00026; other GnRH agonists may help those who experience monthly exacerbations.</div></li><li class="half_rhythm"><div>If menopausal side effects occur, they can be treated by adding low-dose estrogen.&#x000a0;<sup>2</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Prevention of acute attacks in those undergoing surgery</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Minimize preoperative fast as much as possible.</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Provide intravenous glucose (10% dextrose in half-normal saline) in perioperative period.</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Induce anesthesia using non-barbiturate agents that have little or no P450-inducing activity (e.g., propofol, ketamine, short-acting benzodiazepines).</td><td headers="hd_h_hcp.T.prevention_of_acute_attacks_in_cop_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inhalation agents (isoflurane) &#x00026; muscle relaxants also appear to be low-risk for triggering an attack.</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hcp.TF.7.1"><p class="no_margin">Oral contraceptives (birth control pills) are risky and not recommended.</p></div></dd><dt>2. </dt><dd><div id="hcp.TF.7.2"><p class="no_margin"><a class="bk_pop" href="#hcp.REF.andersson.2003.176">Andersson et al [2003]</a></p></div></dd></dl></div></div></div><p><b>Prevention of acute attacks</b>
<b><i>does not</i></b>
<b>involve the following:</b></p><ul><li class="half_rhythm"><div><b>Use of glucose.</b> Because glucose is used to treat acute attacks, its use in <i>preventing</i> attacks has been suggested, and is in fact touted in lay discussions of porphyria; however, there is no evidence that heterozygotes can protect themselves by overeating or adopting a high-carbohydrate diet, and they risk becoming obese. Heterozygotes should adhere to a healthful diet with the usual balance of protein, fat, and carbohydrate. Weight loss is possible but only by incremental restriction of calories combined with exercise. Extreme diets (e.g., all bacon, all brown rice, starvation) are risky and should be avoided.</div></li><li class="half_rhythm"><div><b>Liver transplantation.</b> Because the vast majority of attacks respond to hematin and other supportive measures, liver transplantation has no role in prevention of acute attacks in a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/heterozygote/">heterozygote</a>.</div></li></ul></div><div id="hcp.Surveillance"><h3>Surveillance</h3><p>For those who have chronically elevated ALA (which is infrequent in those who are asymptomatic) and/or are older than age 60 years, an annual assessment of liver and kidney function is recommended.</p><p>Current noninvasive techniques for evaluation of fibrosis in the liver include transient elastography (FibroScan<sup>&#x000ae;</sup>) and a blood-based test (FibroTest<sup>&#x000ae;</sup> or FibroSure<sup>&#x000ae;</sup>) [see <a class="bk_pop" href="#hcp.REF.balwani.2017.1314">Balwani et al 2017</a>]. Note: These assessments have been vetted mainly for people with chronic viral hepatitis or steatohepatitis but may also be useful in porphyria.</p><p>For <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals older than age 60 and anyone with evidence of chronic liver injury, annual screening for hepatocellular carcinoma with abdominal imaging (e.g., ultrasound) and serum alpha-fetoprotein is indicated [<a class="bk_pop" href="#hcp.REF.balwani.2017.1314">Balwani et al 2017</a>].</p></div><div id="hcp.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Avoid the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Extreme caloric deprivation</b> (i.e., total fasting, gastric bypass surgery). A case report of an acute attack occurring in a 23-year-old male who had been taking Hydroxycut<sup>&#x000ae;</sup>, an over-the-counter weight-loss supplement, has been published [<a class="bk_pop" href="#hcp.REF.haimowitz.2015.856">Haimowitz et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Female reproductive hormones.</b> For recommendations regarding contraception, see <a href="#hcp.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Medications.</b> Some drugs are clearly unsafe for <i>CPOX</i> heterozygotes. It is important to note, however, that many other drugs are safe. Providers should not regard individuals with acute porphyria as "untreatable." Compilations of safe and unsafe drugs are available online and are updated as new information becomes available. See <a href="https://porphyriafoundation.org/drug-database" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyriafoundation.org</a>, <a href="http://porphyria.eu/en/content/drugs-and-porphyrias" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a>, or the smartphone app found at <a href="http://porphyriadrugs.com/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyriadrugs.com</a>.</div><div class="half_rhythm">In theory, the most dangerous medications are inducers of CYPs, such as barbiturates and the related compound, phenytoin.</div></li></ul></div><div id="hcp.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate relatives at risk for HCP in order to identify as early as possible those who would benefit from education regarding the risk factors associated with acute attacks.</p><ul><li class="half_rhythm"><div>If the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk relatives.</div></li><li class="half_rhythm"><div>If the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, a <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with symptoms can be evaluated with biochemical tests (see <a href="#hcp.Diagnosis">Diagnosis</a>). Note: Although some <i>CPOX</i> heterozygotes have a diagnostic biochemical profile of heme precursors in urine and feces (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>, <b>Active</b> columns), many have normal findings (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>, <b>Asx</b> [asymptomatic] columns) and can only be diagnosed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li></ul><p>See <a href="#hcp.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="hcp.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The effect of pregnancy on inducing acute attacks is unpredictable. In general, serious problems during pregnancy are unusual. In fact, some women with recurrent symptoms associated with the menstrual cycle report improvement during pregnancy. Attacks, if they occur, are usually in the first trimester. The women most at risk are those with hyperemesis gravidarum and inadequate caloric intake [<a class="bk_pop" href="#hcp.REF.aggarwal.2002.160">Aggarwal et al 2002</a>]. Among antiemetics, ondansetron is not expected to precipitate or exacerbate acute attacks, although several studies have suggested that ondansetron exposure in the first trimester of pregnancy could lead to an increased risk of cleft palate and/or <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> heart defects in the fetus. These suggested risks have not been confirmed. However, metoclopramide should be avoided, as it may precipitate acute attacks [<a class="bk_pop" href="#hcp.REF.shenhav.1997.484">Shenhav et al 1997</a>].</p><p>The experience with administration of hematin (or heme arginate, which is not available in the US) during pregnancy is limited. <a class="bk_pop" href="#hcp.REF.badminton.2006.668">Badminton &#x00026; Deybach [2006]</a> published an anecdotal report of successful heme arginate treatment (without adverse fetal effect) in several women experiencing attacks of variegate porphyria or other acute porphyrias during pregnancy. Based on the absence of reported adverse effects, use of hematin to control exacerbations of acute intermittent porphyria during pregnancy has been recommended [<a class="bk_pop" href="#hcp.REF.isenschmid.1992.1741">Isenschmid et al 1992</a>, <a class="bk_pop" href="#hcp.REF.farfaras.2010.256">Farfaras et al 2010</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="hcp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Hematin for infusion (Panhematin<sup>&#x000ae;</sup>, Recordati Group) is currently the only approved therapy for symptomatic acute porphyria and is a critical part of management. However, it has shortcomings: poor stability in solution; the need for intravenous administration with the attendant risk of phlebitis; interference with coagulation; and iron overload.</p><p>Alternatives are under investigation. One is <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> in which the normal gene (<i>CPOX</i> in the case of hereditary coproporphyria) is targeted to hepatocytes (ClinicalTrials.gov NCT02082860). Another uses small interfering RNA (siRNA) directed against ALA synthase to downregulate hepatic production of ALA and PBG (Givosiran, <a href="http://www.alnylam.com/our-science/capella-rnai-innovation" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Alnylam Pharmaceuticals</a>, Cambridge, MA) (ClinicalTrials.gov NCT02452372). In principle, the latter should be relevant to any of the acute porphyrias. In Phase I-II trials, a single subcutaneous dose of the siRNA reduced ALA synthase and plasma ALA to target levels for a one-month period. Side effects were minor. In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with recurrent symptoms, the need for hematin infusion was reduced. A Phase III clinical trial is currently under way (August 2018).</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="hcp.Genetic_Counseling"><h2 id="_hcp_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hcp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hereditary coproporphyria (HCP) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hcp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><ul><li class="half_rhythm"><div>Most individuals with HCP have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with HCP may harbor a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The proportion of HCP caused by a <i>de novo</i> pathogenic variant is unknown.</div></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>CPOX</i> pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>Evaluation of parents may determine that one has a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but has not been previously diagnosed because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Therefore, an apparently negative family history cannot be confirmed until <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the proband, the risk to the sibs of inheriting the <i>CPOX</i> pathogenic variant is 50%. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, many individuals heterozygous for a <i>CPOX</i> pathogenic variant do not manifest signs and symptoms of HCP.</div></li><li class="half_rhythm"><div>If the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with HCP has a 50% chance of inheriting the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Because of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>, many individuals with a <i>CPOX</i> pathogenic variant do not manifest signs and symptoms of HCP.</p><p><b>Other family members.</b>The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="hcp.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hcp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with HCP has the <i>CPOX</i> pathogenic variant or clinical evidence of the disorder, the <i>CPOX</i> pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be considered.</p><p><b>Testing of at-risk asymptomatic relatives</b> of individuals with HCP is possible after <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has identified the specific <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family. Such testing should be performed in the context of formal <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. The results of molecular genetic testing are not useful in predicting age of onset, severity, or specific symptoms. Note: Although some <i>CPOX</i> heterozygotes have a diagnostic biochemical profile of heme precursors in urine and feces (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>, <b>Active</b> columns), many have normal biochemical test results (see <a class="figpopup" href="/books/NBK114807/table/hcp.T.biochemical_characteristics_of_her/?report=objectonly" target="object" rid-figpopup="fighcpTbiochemicalcharacteristicsofher" rid-ob="figobhcpTbiochemicalcharacteristicsofher">Table 1</a>, <b>Asx</b> [asymptomatic] columns) and can be diagnosed only by molecular genetic testing.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hcp.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for HCP are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the purpose is pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate. Parents are encouraged to seek <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> before reaching a decision on the use of prenatal testing.</p><p>Note: The presence of a <i>CPOX</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detected by prenatal testing does not predict whether individuals will be symptomatic, or if they are, what the severity of the clinical manifestations will be. It is common for the offspring who inherit the <i>CPOX</i> pathogenic variant from a severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual to be completely asymptomatic.</p></div></div><div id="hcp.Resources"><h2 id="_hcp_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Porphyria Foundation (APF)</b></div><div>915 St. Elmo Avenue</div><div>Suite 200</div><div>Bethesda MD 20814</div><div><b>Phone:</b> 866-APF-3635 (toll-free); 301-347-7166</div><div><b>Email:</b> porphyrus@porphyriafoundation.com</div><div><a href="https://www.porphyriafoundation.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org</a></div></li><li class="half_rhythm"><div><b>British &#x00026; Irish Porphyria Network (BIPNET)</b></div><div>United Kingdom</div><div><a href="http://www.bipnet.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.bipnet.org.uk</a></div></li><li class="half_rhythm"><div><b>British Porphyria Association</b></div><div>United Kingdom</div><div><b>Phone:</b> 0300 30 200 30</div><div><b>Email:</b> helpline@porphyria.org.uk</div><div><a href="http://www.porphyria.org.uk/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyria.org.uk</a></div></li><li class="half_rhythm"><div><b>Canadian Association for Porphyria/Association Canadienne de Porphyrie</b></div><div>Canada</div><div><a href="http://canadianassociationforporphyria.ca/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.canadianassociationforporphyria.ca</a></div></li><li class="half_rhythm"><div><b>Find a Porphyria Expert</b></div><div>American Porphyria Foundation</div><div><a href="https://www.porphyriafoundation.org/for-patients/porphyria-experts/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porphyriafoundation.org/for-patients/porphyria-experts</a></div></li><li class="half_rhythm"><div><b>National Acute Porphyria Service (NAPS)</b></div><div>United Kingdom</div><div><b>Phone:</b> +44 29 2184 7747</div><div><a href="http://www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cardiffandvaleuhb.wales.nhs.uk/national-acute-porphyria-service-naps</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=hereditarycoproporphyria" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary coproporphyria</a></div></li><li class="half_rhythm"><div><b>Porphyria South Africa</b></div><div>South Africa</div><div><b>Phone:</b> +27 21-4066332</div><div><b>Fax:</b> +27 21-4066061</div><div><b>Email:</b> Peter.Meissner@uct.ac.za</div><div><a href="http://www.porphyria-patients.uct.ac.za/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Porphyria for Patients</a></div></li><li class="half_rhythm"><div><b>Welsh Medicines Information Centre</b></div><div><i>The Welsh Medicines Information Centre (WMIC) offers a specialist advisory service on the safe use of drugs in porphyria.</i></div><div>United Kingdom</div><div><b>Phone:</b> +44 029 2074 4298</div><div><a href="https://www.wmic.wales.nhs.uk/specialist-services/drugs-in-porphyria/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Drugs in Porphyria</a></div></li><li class="half_rhythm"><div><b>European Porphyria Network</b></div><div><b>Email:</b> contact@porphyria.eu</div><div><a href="http://porphyria.eu/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">porphyria.eu</a></div></li><li class="half_rhythm"><div><b>Swedish Porphyria Patients' Association</b></div><div>Karolinska Universitetssjukhuset</div><div>Huddinge M 96</div><div>Stockholm Stockholms Lan SE-141 86</div><div>Sweden</div><div><b>Phone:</b> +46 8 711 56 09 </div><div><b>Email:</b> porfyrisjukdomar@gmail.com</div><div><a href="http://www.porfyri.se" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.porfyri.se</a></div></li></ul></div><div id="hcp.Molecular_Genetics"><h2 id="_hcp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hcp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hereditary Coproporphyria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hcp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hcp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hcp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hcp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hcp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hcp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hcp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1371" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CPOX</i></a></td><td headers="hd_b_hcp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1371" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">3q11<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_hcp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P36551" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial</a></td><td headers="hd_b_hcp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/CPOX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CPOX database</a></td><td headers="hd_b_hcp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CPOX" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CPOX</a></td><td headers="hd_b_hcp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CPOX[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CPOX</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hcp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hcp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hereditary Coproporphyria (<a href="/omim/121300,612732" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK114807/table/hcp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hcp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/121300" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">121300</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COPROPORPHYRIA, HEREDITARY; HCP</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612732" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612732</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">COPROPORPHYRINOGEN OXIDASE; CPOX</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>CPOX</i> comprises seven exons; the reference sequence of the transcript is <a href="/nuccore/NM_000097.5" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000097.5</a>. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK114807/#hcp.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Pathogenic variants in all seven exons have been identified in persons with HCP (Human Gene Mutation Database, updated from <a class="bk_pop" href="#hcp.REF.rosipal.1999.44">Rosipal et al [1999]</a>). They include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, small deletions, insertions, indels, splice variants, and large deletions.</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Coproporphyringen-III oxidase (synonyms: coproporphyrinogen oxidase and coproporphyrinogen decarboxylase), the product of <i>CPOX</i>, performs an oxidative decarboxylation without a metal, reducing agents, or obligatory cofactors. The details of this unusual reaction remain to be elucidated. The crystal structure of human coproporphyringen-III oxidase points to a dimer as the catalytically active unit.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Some <i>CPOX</i> pathogenic variants likely alter enzyme activity by disrupting dimer formation [<a class="bk_pop" href="#hcp.REF.lee.2005.14232">Lee et al 2005</a>].</p><p>The 110-residue N-terminal segment is responsible for targeting the enzyme to mitochondria and is the site of its action on the substrate, coproporphyrinogen. Pathogenic variants in this region may affect <a class="def" href="/books/n/gene/glossary/def-item/translocation/">translocation</a> of the protein and, thus, reduce enzymatic function in tissues without changing activity in cell extracts.</p></div><div id="hcp.References"><h2 id="_hcp_References_">References</h2><div id="hcp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.aggarwal.2002.160">Aggarwal N, Bagga R, Sawhney H, Suri V, Vasishta K. Pregnancy with acute intermittent porphyria: a case report and review of literature. <span><span class="ref-journal">J Obstet Gynaecol Res. </span>2002;<span class="ref-vol">28</span>:160–2.</span> [<a href="/pubmed/12214832" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12214832</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.akagi.2006.237">Akagi R, Inoue R, Muranaka S, Tahara T, Taketani S, Anderson KE, Phillips JD, Sassa S. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. <span><span class="ref-journal">Br J Haematol. </span>2006;<span class="ref-vol">132</span>:237–43.</span> [<a href="/pubmed/16398658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16398658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.anderson.2005.439">Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, Desnick RJ. Recommendations for the diagnosis and treatment of the acute porphyrias. <span><span class="ref-journal">Ann Intern Med. </span>2005;<span class="ref-vol">142</span>:439–50.</span> [<a href="/pubmed/15767622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15767622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.anderson.2006.537">Anderson KE, Bonkovsky HL, Bloomer JR, Shedlofsky SI. Reconstitution of hematin for intravenous infusion. <span><span class="ref-journal">Ann Intern Med. </span>2006;<span class="ref-vol">144</span>:537–8.</span> [<a href="/pubmed/16585674" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16585674</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.andersson.2003.176">Andersson C, Innala E, B&#x000e4;ckstr&#x000f6;m T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. <span><span class="ref-journal">J Intern Med. </span>2003;<span class="ref-vol">254</span>:176–83.</span> [<a href="/pubmed/12859699" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12859699</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.badminton.2006.668">Badminton MN, Deybach JC. Treatment of an acute attack of porphyria during pregnancy. <span><span class="ref-journal">Eur J Neurol. </span>2006;<span class="ref-vol">13</span>:668–9.</span> [<a href="/pubmed/16796597" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16796597</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.balwani.2017.1314">Balwani M, Wang B, Anderson KE, Bloomer JR, Bissell DM, Bonkovsky HL, Phillips JD, Desnick RJ, et al.  Acute hepatic porphyrias: recommendations for evaluation and long-term management. <span><span class="ref-journal">Hepatology. </span>2017;<span class="ref-vol">66</span>:1314–22.</span> [<a href="/pmc/articles/PMC5605422/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5605422</span></a>] [<a href="/pubmed/28605040" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28605040</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.barbaro.2012.249">Barbaro M, Kotaj&#x000e4;rvi M, Harper P, Floderus Y. Identification of an AluY-mediated deletion of exon 5 in the CPOX gene by MLPA analysis in patients with hereditary coproporphyria. <span><span class="ref-journal">Clin Genet. </span>2012;<span class="ref-vol">81</span>:249–56.</span> [<a href="/pubmed/21231929" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21231929</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.billing.1978.481">Billing BH. Twenty-five years of progress in bilirubin metabolism (1952-77). <span><span class="ref-journal">Gut. </span>1978;<span class="ref-vol">19</span>:481–91.</span> [<a href="/pmc/articles/PMC1412033/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1412033</span></a>] [<a href="/pubmed/98394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 98394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.bissell.2015.313">Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. <span><span class="ref-journal">Am J Med. </span>2015;<span class="ref-vol">128</span>:313–7.</span> [<a href="/pmc/articles/PMC4339446/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4339446</span></a>] [<a href="/pubmed/25446301" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25446301</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.blake.1992.96">Blake D, McManus J, Cronin V, Ratnaike S. Fecal coproporphyrin isomers in hereditary coproporphyria. <span><span class="ref-journal">Clin Chem. </span>1992;<span class="ref-vol">38</span>:96–100.</span> [<a href="/pubmed/1733615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1733615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.bonkovsky.2008.2813">Bonkovsky HL, Siao P, Roig Z, Hedley-Whyte ET, Flotte TJ. Case records of the Massachusetts General Hospital. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. <span><span class="ref-journal">N Engl J Med. </span>2008;<span class="ref-vol">358</span>:2813–25.</span> [<a href="/pubmed/18579817" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18579817</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.brodie.1977.229">Brodie MJ, Thompson GG, Moore MR, Beattie AD, Goldberg A. Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. <span><span class="ref-journal">Q J Med. </span>1977;<span class="ref-vol">46</span>:229–41.</span> [<a href="/pubmed/866576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 866576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.dowman.2011.571">Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome PN. Liver transplantation from donors with acute intermittent porphyria. <span><span class="ref-journal">Ann Intern Med. </span>2011;<span class="ref-vol">154</span>:571–2.</span> [<a href="/pubmed/21502660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21502660</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.farfaras.2010.256">Farfaras A, Zagouri F, Zografos G, Kostopoulou A, Sergentanis TN, Antoniou S. Acute intermittent porphyria in pregnancy: a common misdiagnosis. <span><span class="ref-journal">Clin Exp Obstet Gynecol. </span>2010;<span class="ref-vol">37</span>:256–60.</span> [<a href="/pubmed/21355451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21355451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.gibson.2000.192">Gibson PR, Grant J, Cronin V, Blake D, Ratnaike S. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alpha on porphyrin profiles in plasma, urine and faeces. <span><span class="ref-journal">J Gastroenterol Hepatol. </span>2000;<span class="ref-vol">15</span>:192–201.</span> [<a href="/pubmed/10735544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10735544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.goetsch.1986.235">Goetsch CA, Bissell DM. Instability of hematin used in the treatment of acute hepatic porphyria. <span><span class="ref-journal">N Engl J Med. </span>1986;<span class="ref-vol">315</span>:235–8.</span> [<a href="/pubmed/3724815" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3724815</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.grimes.2016.2142">Grimes R, Gilleece Y, Appleby T, Stockwell S, Pinto-Sander N, Sahabandu T, Stein P, Bradshaw D. A case of hereditary coproporphyria precipitated by efavirenz. <span><span class="ref-journal">AIDS. </span>2016;<span class="ref-vol">30</span>:2142–3.</span> [<a href="/pubmed/27465283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27465283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.haimowitz.2015.856">Haimowitz S, Hsieh J, Shcherba M, Averbukh Y. Liver failure after Hydroxycut&#x02122; use in a patient with undiagnosed hereditary coproporphyria. <span><span class="ref-journal">J Gen Intern Med. </span>2015;<span class="ref-vol">30</span>:856–9.</span> [<a href="/pmc/articles/PMC4441672/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4441672</span></a>] [<a href="/pubmed/25666208" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25666208</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.hasanoglu.2011.225">Hasanoglu A, Balwani M, Kasapkara CS, Ezg&#x000fc; FS, Okur I, T&#x000fc;mer L, Cakmak A, Nazarenko I, Yu C, Clavero S, Bishop DF, Desnick RJ. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. <span><span class="ref-journal">J Inherit Metab Dis. </span>2011;<span class="ref-vol">34</span>:225–31.</span> [<a href="/pmc/articles/PMC3091031/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3091031</span></a>] [<a href="/pubmed/21103937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21103937</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.hasegawa.2017.99">Hasegawa K, Tanaka H, Yamashita M, Higuchi Y, Miyai T, Yoshimoto J, Okada A, Suzuki N, Iwatsuki K, Tsukahara H. Neonatal-onset hereditary coproporphyria: a new variant of hereditary coproporphyria. <span><span class="ref-journal">JIMD Rep. </span>2017;<span class="ref-vol">37</span>:99–106.</span> [<a href="/pmc/articles/PMC5740044/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5740044</span></a>] [<a href="/pubmed/28349448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28349448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.isenschmid.1992.1741">Isenschmid M, K&#x000f6;nig C, F&#x000e4;ssli C, Haenel A, H&#x000e4;nggi W, Schneider H. Acute intermittent porphyria in pregnancy: glucose or hematin therapy? <span><span class="ref-journal">Schweiz Med Wochenschr. </span>1992;<span class="ref-vol">122</span>:1741–5.</span> [<a href="/pubmed/1448679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1448679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.jaraprado.2000.404">Jara-Prado A, Yescas P, S&#x000e1;nchez FJ, R&#x000ed;os C, Garnica R, Alonso E. Prevalence of acute intermittent porphyria in a Mexican psychiatric population. <span><span class="ref-journal">Arch Med Res. </span>2000;<span class="ref-vol">31</span>:404–8.</span> [<a href="/pubmed/11068084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11068084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.k_hnel.2000.465">K&#x000fc;hnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. <span><span class="ref-journal">Clin Biochem. </span>2000;<span class="ref-vol">33</span>:465–73.</span> [<a href="/pubmed/11074238" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11074238</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.lambie.2018.616">Lambie D, Florkowski C, Sies C, Raizis A, Siu WK, Towns C. A case of hereditary coproporphyria with posterior reversible encephalopathy and novel coproporphyrinogen oxidase gene mutation c.863T&#x0003e;G (p.Leu288Trp). <span><span class="ref-journal">Ann Clin Biochem. </span>2018;<span class="ref-vol">55</span>:616–19.</span> [<a href="/pubmed/29660996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29660996</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.lamoril.2001.1130">Lamoril J, Puy H, Whatley SD, Martin C, Woolf JR, Da Silva V, Deybach JC, Elder GH. Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">68</span>:1130–8.</span> [<a href="/pmc/articles/PMC1226094/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1226094</span></a>] [<a href="/pubmed/11309681" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11309681</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.lee.2005.14232">Lee DS, Flachsov&#x000e1; E, Bodn&#x000e1;rov&#x000e1; M, Demeler B, Mart&#x000e1;sek P, Raman CS. Structural basis of hereditary coproporphyria. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2005;<span class="ref-vol">102</span>:14232–7.</span> [<a href="/pmc/articles/PMC1224704/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1224704</span></a>] [<a href="/pubmed/16176984" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16176984</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.ma.2011.135">Ma E, Mar V, Varigos G, Nicoll A, Ross G. Haem arginate as effective maintenance therapy for hereditary coproporphyria. <span><span class="ref-journal">Australas J Dermatol. </span>2011;<span class="ref-vol">52</span>:135–8.</span> [<a href="/pubmed/21605099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21605099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.rosipal.1999.44">Rosipal R, Lamoril J, Puy H, Da Silva V, Gouya L, De Rooij FW, Te Velde K, Nordmann Y, Mart&#x000e0;sek P, Deybach JC. Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">13</span>:44–53.</span> [<a href="/pubmed/9888388" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9888388</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.sadeh.1991.712">Sadeh M, Blatt I, Martonovits G, Karni A, Goldhammer Y. Treatment of porphyric convulsions with magnesium sulfate. <span><span class="ref-journal">Epilepsia. </span>1991;<span class="ref-vol">32</span>:712–5.</span> [<a href="/pubmed/1915181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1915181</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.sardh.2013.1063">Sardh E, Wahlin S, Bj&#x000f6;rnstedt M, Harper P, Andersson DE. High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013;<span class="ref-vol">36</span>:1063–71.</span> [<a href="/pubmed/23344888" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23344888</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.schmitt.2005.3089">Schmitt C, Gouya L, Malonova E, Lamoril J, Camadro JM, Flamme M, Rose C, Lyoumi S, Da Silva V, Boileau C, Grandchamp B, Beaumont C, Deybach JC, Puy H. Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. <span><span class="ref-journal">Hum Mol Genet. </span>2005;<span class="ref-vol">14</span>:3089–98.</span> [<a href="/pubmed/16159891" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16159891</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.shenhav.1997.484">Shenhav S, Gemer O, Sassoon E, Segal S. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. <span><span class="ref-journal">Acta Obstet Gynecol Scand. </span>1997;<span class="ref-vol">76</span>:484–5.</span> [<a href="/pubmed/9197454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9197454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.soonawalla.2004.705">Soonawalla ZF, Orug T, Badminton MN, Elder GH, Rhodes JM, Bramhall SR, Elias E. Liver transplantation as a cure for acute intermittent porphyria. <span><span class="ref-journal">Lancet. </span>2004;<span class="ref-vol">363</span>:705–6.</span> [<a href="/pubmed/15001330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15001330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.tran.2013.116">Tran TP, Leduc K, Savard M, Dupr&#x000e9; N, Rivest D, Nguyen DK. Acute porphyria presenting as epilepsia partialis continua. <span><span class="ref-journal">Case Rep Neurol. </span>2013;<span class="ref-vol">5</span>:116–24.</span> [<a href="/pmc/articles/PMC3724138/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3724138</span></a>] [<a href="/pubmed/23898283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23898283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.van_de_steeg.2012.519">van de Steeg E, Str&#x000e1;neck&#x000fd; V, Hartmannov&#x000e1; H, Noskov&#x000e1; L, H&#x00159;eb&#x000ed;&#x0010d;ek M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticov&#x000e1; E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. <span><span class="ref-journal">J Clin Invest. </span>2012;<span class="ref-vol">122</span>:519–28.</span> [<a href="/pmc/articles/PMC3266790/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3266790</span></a>] [<a href="/pubmed/22232210" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22232210</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.van_tuyll_van_serooskerken.2011.2249">van Tuyll van Serooskerken AM, de Rooij FW, Edixhoven A, Bladergroen RS, Baron JM, Joussen S, Merk HF, Steijlen PM, Poblete-Guti&#x000e9;rrez P, te Velde K, Wilson JH, Koole RH, van Geel M, Frank J. Digenic inheritance of mutations in the coproporphyrinogen oxidase and protoporphyrinogen oxidase genes in a unique type of porphyria. <span><span class="ref-journal">J Invest Dermatol. </span>2011;<span class="ref-vol">131</span>:2249–54.</span> [<a href="/pubmed/21734717" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21734717</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.vercesi.1994.86">Vercesi AE, Castilho RF, Meinicke AR, Valle VG, Hermes-Lima M, Bechara EJ. Oxidative damage of mitochondria induced by 5-aminolevulinic acid: role of Ca2+ and membrane protein thiols. <span><span class="ref-journal">Biochim Biophys Acta. </span>1994;<span class="ref-vol">1188</span>:86–92.</span> [<a href="/pubmed/7947907" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7947907</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hcp.REF.whatley.2009.1406">Whatley SD, Mason NG, Woolf JR, Newcombe RG, Elder GH, Badminton MN. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. <span><span class="ref-journal">Clin Chem. </span>2009;<span class="ref-vol">55</span>:1406–14.</span> [<a href="/pubmed/19460837" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19460837</span></a>]</div></li></ul></div></div><div id="hcp.Chapter_Notes"><h2 id="_hcp_Chapter_Notes_">Chapter Notes</h2><div id="hcp.Acknowledgments"><h3>Acknowledgments</h3><p>The work has been carried out under the auspices of the Porphyria Rare Disease Clinical Research Consortium (KE Anderson, Galveston, TX; DM Bissell, San Francisco, CA; JR Bloomer, Birmingham AL; HL Bonkowsky, Charlotte, NC; RJ Desnick, New York, NY; and JD Phillips, Salt Lake City, UT). The Consortium receives essential support from the NIH/NIDDK (1 U54 DK083909) and the American Porphyria Foundation.</p></div><div id="hcp.Author_History"><h3>Author History</h3><p>D Montgomery Bissell, MD (2012-present)<br />Theora Cimino, BS; University of California San Francisco (2012-2015)<br />Jennifer Lai, MD; University of California San Francisco (2012-2018)<br />Bruce Wang, MD (2012-present)</p></div><div id="hcp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>8 November 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>1 July 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 December 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>9 April 2012 (mb/bw) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK114807</span><span class="label">PMID: <a href="/pubmed/23236641" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">23236641</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/ataxias/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/hgc/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK114807&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK114807/?report=reader">PubReader</a></li><li><a href="/books/NBK114807/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK114807" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK114807" style="display:none" title="Cite this Page"><div class="bk_tt">Wang B, Bissell DM. Hereditary Coproporphyria. 2012 Dec 13 [Updated 2018 Nov 8]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK114807/pdf/Bookshelf_NBK114807.pdf">PDF version of this page</a> (553K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hcp.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hcp.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hcp.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hcp.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hcp.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hcp.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hcp.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hcp.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hcp.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hcp.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hcp.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1371[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CPOX</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2994942" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2994942" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2994942" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2994942" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409300" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Variegate Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Singal AK, Anderson KE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301372" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Acute Intermittent Porphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Whatley SD, Badminton MN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301512" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypokalemic Periodic Paralysis<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Weber F, Lehmann-Horn F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23016163" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Erythropoietic Protoporphyria, Autosomal Recessive<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Bloomer J, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23409301" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> X-Linked Protoporphyria<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Balwani M, Desnick R, Porphyrias Consortium of the NIH-Sponsored Rare Diseases Clinical Research Network. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=23236641" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=23236641" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04169739a66ee2ba1e35c3">Hereditary Coproporphyria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hereditary Coproporphyria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T21:10:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C1179E0407E51000000000637022B&amp;ncbi_session=CE8C1179E0416961_1591SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK114807%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK114807&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK114807/&amp;ncbi_pagename=Hereditary Coproporphyria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C1179E0416961_1591SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>